API | xmab20717

xmab20717 Report issue

Biologics mAb Multi-specific Experimental

Active Ingredient History

NOW

Now

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: Yes
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (27)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (27)

Adenocarcinoma, Clear Cell (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma, Basal Cell (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Neuroendocrine (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Cholangiocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 1)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Melanoma (Phase 1)

Mesothelioma (Phase 1)

Nasopharyngeal Carcinoma (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Adnexal and Skin Appendage (Phase 1)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Salivary Gland Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Thymoma (Phase 1)

Uterine Cervical Neoplasms (Phase 2)

Vulvar Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue